PET117, a conserved mitochondrial protein, is significantly overexpressed in cervical cancer tissue and acts as a pro-ferroptotic regulator. Knocking out PET117 in HeLa cells markedly suppressed ferroptosis triggered by two canonical inducers — erastin (a system Xc- inhibitor) and RSL3 (a GPX4 inhibitor) — by attenuating intracellular ROS accumulation, lipid peroxidation, and iron overload. Integrative mitochondrial proteomics and RNA-seq identified acyl-CoA synthetase family member 2 (ACSF2), a fatty acid activation enzyme, as a downstream effector whose downregulation mediates PET117-loss-conferred ferroptosis resistance.
Ferroptosis has attracted intense oncology interest precisely because cancer cells evading conventional apoptosis often remain vulnerable to lipid-peroxidation-mediated death. Most ferroptosis research has centered on cytosolic regulators — GPX4, SLC7A11, FSP1 — so identifying a mitochondrial gatekeeper like PET117 meaningfully expands the mechanistic map. The PET117→ACSF2 axis is especially notable: ACSF2 activates long-chain fatty acids destined for mitochondrial β-oxidation, suggesting that mitochondrial lipid metabolism is not merely collateral in ferroptosis but causally upstream. For cervical cancer specifically, where platinum-based chemoresistance is a persistent clinical problem, PET117 or ACSF2 could serve as biomarkers of ferroptosis competence or therapeutic co-targets. Limitations are significant: findings are limited to HeLa cells with no in vivo validation, and causality through ACSF2 requires direct rescue experiments. Nonetheless, the mitochondrial-proteome-level resolution makes this more than incremental — it is a mechanistically clarifying contribution warranting follow-up in primary tumor models.